Cantor Fitzgerald analyst Louise Chen said that a news articles, which she attributed to Street Account, stated that Perrigo (PRGO) may be interested in acquiring Akorn (AKRX). However, after she had a chance to speak to investor relations at Perrigo she said that she thinks "based on what the company has factually put out there in terms of its M&A strategy" that this deal would not make sense. She noted that Perrigo has been interested in divesting its generics business and bringing on another mostly generics asset would further delay its intended strategy. Chen has an Overweight rating on Perrigo shares. The Fly notes that a report in Okdiario was cited by its trading contacts as the source of the Perrigo for Akorn talks rumor.

Perrigo announced that pharmaceutical company Esteve Healthcare has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to EUR 275M, consisting of an upfront cash payment of EUR 190M and up to EUR 85M in potential earnout payments based on the Rare Diseases business achieving certain sales milestones. Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by Esteve and enter into a definitive agreement with Esteve for the sale of the Rare Diseases business. The proposed final transaction is expected to close during the third quarter of 2024, subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals.